Nektar Therapeutics (NKTR) Return on Invested Capital (2016 - 2025)
Historic Return on Invested Capital for Nektar Therapeutics (NKTR) over the last 15 years, with Q3 2025 value amounting to 3.21%.
- Nektar Therapeutics' Return on Invested Capital fell 8300.0% to 3.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.21%, marking a year-over-year decrease of 8300.0%. This contributed to the annual value of 1.1% for FY2024, which is 400.0% down from last year.
- According to the latest figures from Q3 2025, Nektar Therapeutics' Return on Invested Capital is 3.21%, which was down 8300.0% from 19.18% recorded in Q2 2025.
- Nektar Therapeutics' 5-year Return on Invested Capital high stood at 19.18% for Q2 2025, and its period low was 3.21% during Q3 2025.
- For the 5-year period, Nektar Therapeutics' Return on Invested Capital averaged around 0.31%, with its median value being 1.27% (2024).
- Within the past 5 years, the most significant YoY rise in Nektar Therapeutics' Return on Invested Capital was 207600bps (2025), while the steepest drop was -17900bps (2025).
- Quarter analysis of 5 years shows Nektar Therapeutics' Return on Invested Capital stood at 0.6% in 2021, then tumbled by -62bps to 0.97% in 2022, then plummeted by -86bps to 1.81% in 2023, then fell by -6bps to 1.92% in 2024, then plummeted by -68bps to 3.21% in 2025.
- Its Return on Invested Capital stands at 3.21% for Q3 2025, versus 19.18% for Q2 2025 and 3.07% for Q1 2025.